Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 15/20 | 0.33 |
| ▸ | JAK2 | O60674 | 14/20 | 0.33 |
| ▸ | JAK1 | P23458 | 13/20 | 0.33 |
| ▸ | TYK2 | P29597 | 12/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MELK | Q14680 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27153783 | 1.00 | IRAK4 (0.37) | IRAK4JAK3JAK2JAK1TYK2 | |
| SCHEMBL30822849 | 1.00 | IRAK4 (0.37) | IRAK4JAK3JAK2JAK1TYK2 | |
| SCHEMBL20051455 | 0.85 | PIK3CD (0.33) | IRAK4JAK1 | |
| SCHEMBL20051452 | 0.85 | PIK3CD (0.33) | IRAK4JAK1 | |
| SCHEMBL21286839 | 0.85 | PIK3CD (0.33) | IRAK4JAK1 | |
| SCHEMBL25806402 | 0.85 | PIK3CD (0.33) | IRAK4JAK1 | |
| SCHEMBL25806613 | 0.85 | PIK3CD (0.33) | IRAK4JAK1 | |
| SCHEMBL20051777 | 0.85 | IRAK4 (0.39) | IRAK4MELK | |
| Hydrochloric Acid SCHEMBL25301238 | 0.84 | PIK3CD (0.33) | IRAK4JAK1 | |
| Hydrochloric Acid SCHEMBL31382910 | 0.84 | PIK3CD (0.33) | IRAK4JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024041586-A1 | PRODRUG OF JAK KINASE INHIBITOR | 启元生物(杭州)有限公司 | 2024-02-29 | — | — | WO | disclosed |
| US-10738060-B2 | JAK1 selective inhibitors and uses thereof | TLL Pharmaceutical, LLC (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190256523-A1 | NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF | HANGZHOU HIGHLIGHTII PHARMACEUTICAL CO., LTD (CN) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738060-B2 | JAK1 selective inhibitors and uses thereof | JAK1, JAK3, JAK2 | IRAK4 11/4885JAK3 2/4885JAK2 3/4885 |
| US-20190256523-A1 | NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF | JAK1, JAK3, JAK2 | IRAK4 11/4885JAK3 2/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.